Using Automated Spinoculation For CAR T Cell Lentiviral Transduction

The landscape of cancer treatment is experiencing a significant transformation through the advancement and utilization of T cell immunotherapies, marking a pivotal moment for the clinical and biopharmaceutical sectors. The approval of autologous CAR T cell therapies Kymriah™ from Novartis and Yescarta™ from Gilead/Kite underscores the increasing need for automated and closed solutions in cell and gene therapy manufacturing. The industrialization of these processes will require improved risk management, scalability, and reproducibility.

While automation equipment exists for most of the workflow steps of CAR T cell therapy manufacturing, certain steps, notably lentiviral transduction for gene transfer, necessitate enhanced methods and technologies. SpinOculation C-Pro application software has been introduced to streamline and automate lentiviral transduction for gene transfer in CAR T cell therapies while maintaining flexibility during process development. Observe how this standalone solution was utilized in two different workflows, demonstrating its capability as a solution for a closed, automated lentiviral vector transduction step where transduction efficiency can rival that of a manual, open process.